市場調查報告書
商品編碼
1087068

骨化二醇:市場預測(2022-2027)

Calcifediol Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計 2020 年全球骨化二醇市場將增長至 1,242,33,000 美元,在預測期內以 9.27% 的複合年增長率增長至 2,239,841,000 美元,預計 2027 年將增長。推動市場發展的因素包括中國和印度等新興國家對先進醫藥原料 (API) 生產的支出增加,以及飲食習慣的改變和快節奏的工作環境導致慢性腎病 (CKD)。)全球流行率正在上升。

本報告探討了骨化二醇的全球市場,包括市場規模和預測、市場驅動因素和挑戰、市場趨勢、細分市場分析、競爭條件和主要參與者的概況。提供有關的系統信息。

目錄

第一章介紹

  • 市場定義
  • 市場細分

第二章調查方法

  • 調查數據
  • 假設

第 3 章執行摘要

  • 調查重點

第四章市場動態

  • 市場促進因素
  • 市場製約因素
  • 波特五力分析
    • 終端用戶議價能力
    • 買方的議價能力
    • 新進入者的威脅
    • 替代威脅
    • 競爭對手之間的敵對關係
  • 產業價值鏈分析

第 5 章骨化二醇市場分析:按應用

  • 簡介
  • 嬰幼兒藥
  • 動物飼料
  • 其他

第 6 章骨化二醇市場分析:按地區劃分

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 其他
  • 中東和非洲
    • 沙特阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 印度尼西亞
    • 泰國
    • 台灣
    • 其他

第7章競爭態勢與分析

  • 主要公司及戰略分析
  • 初創企業和市場優勢
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第 8 章公司簡介

  • Chemvon Biotechnology Co
  • Cayman Chemicals
  • Haoyuan Chemexpress Co., Ltd
  • Pharmaceutical Research Institute (PRI)
  • BOC Sciences
  • BLDpharm
  • Pharmaffiliates
  • ChemScence
  • ApexBio Technology
目錄
Product Code: KSI061614181

The calcifediol market is evaluated at US$1,204.233 million for the year 2020 and is projected to grow at a CAGR of 9.27% to reach a market size of US$2,239.841 million by the year 2027.

Calcifediol monohydrate (25-Hydroxyvitamin D3) is a vitamin D3 analogue created by hydroxylation of vitamin D3 (cholecalciferol) using the enzyme cholecalciferol 25-hydroxylase. Increasing expenditures on advanced pharmaceutical ingredients (API) manufacturing in emerging economies such as China and India is expected to keep the calcifediol monohydrate market growing. Furthermore, the global prevalence of chronic kidney disease (CKD) is increasing as a result of changing dietary patterns and a fast-paced work environment, which is boosting the demand for calcifediol monohydrate-based medications. According to the National Centre for Chronic Disease Prevention and Health Promotion (USA), chronic kidney disease affects about 15% of the population in the United States (CKD).

Additionally, the higher incidence of rickets and brittle bones is predicted to boost this industry's growth. According to the Centers for Disease Control and Prevention, rickets affects 5 out of every 1,000,000 children aged 6 months to 5 years. Also, companies are investing heavily in research and development. Because of the advantageous legislation regulating the manufacture and sale of vitamin D analogues and vitamin D3 APIs, leading manufacturers are locating their manufacturing facilities in Europe.

On the other hand, due to the high concentration and purity of vitamin D, the manufacture of this chemical necessitates the use of technologically advanced machinery and high monetary backup, along with factors affecting regulation and standardisation, which stifle industry growth to some extent.

Animal feed, pharmaceuticals, and others are the three application segments that make up the global calcifediol monohydrate market. The usage of calcifediol monohydrate in personal grooming and nutraceutical applications is covered under the other application areas. Broilers, cattle, breeders, and swine are projected to employ calcifediol monohydrate as an important source for calcium and phosphorus absorption in the body and calcium mobilization in bones in the animal sector. Additionally, it aids in the improvement of immune cells. Because of its widespread use in health supplements, injectables, and capsules, the pharmaceuticals segment is also expected to develop at a high CAGR During the forecast period.

The largest market, Asia Pacific, accounts for a considerable portion of the global calcifediol monohydrate market. Vitamin D deficiency is widespread throughout Asia Pacific, particularly in South - East Asia. Rickets is a disease induced by a deficiency of vitamin D that is particularly frequent in China. Furthermore, increasing income levels and significant consumer demand for nutritious and healthy products are anticipated to provide promising prospects for the expansion and development of the region's functional food and beverage products, resulting in increased consumption of vitamin-infused products and, as a result, market growth. Animal feed accounted for a majority of the calcifediol monohydrate generated in the region. The demand for animal feed is predicted to rise as the region's livestock production grows. Moreover, Europe is the second-largest user of calcifediol monohydrate after the United States. Because of the increased prevalence of kidney illnesses, the region is likely to grow rapidly.

COVID-19 Impact

The COVID-19 outbreak caused a substantially positive effect on the calcifediol market. Increasing evidence suggests that vitamin D plays a preventive role in lowering the risk and severity of respiratory tract infections (RTIs), particularly in the context of influenza and COVID-19. Major clinical findings demonstrate that vitamin D insufficiency has a role in the SARS-CoV-2 acute respiratory distress syndrome (ARDS) and that case fatality rates rise with age and SARS-CoV-2 serum concentrations. A multi-centre observational analysis of 537 COVID-19 patients found that those who received calcifediol had a lower mortality rate during the first 30 days of hospitalisation than those who did not. As a result, the calcifediol market had a significant role to play amid the COVID-19 pandemic.

Recent Development

DSM (Netherlands) and Zhejiang Xinhecheng Co Ltd. (China) inked a contract for the sale and purchase of cholesterol in January 2019. Vitamin D3 is made from cholesterol. This deal assisted the organisation in increasing its total capacity and Vitamin D productivity.

Fermenta Biotech Limited (India) signed a 99-year lease deal with the Gujarat Industrial Development Corporation (GIDC) authority in Ankleshwar, Sayakha in January 2019 to acquire a 40,000-square-meter plot of land for future expansion.

Market Segmentation

  • By Application

Pharmaceutical

Animal feed

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Calcifediol Market Analysis, by Application

  • 5.1. Introduction
  • 5.2. Infant Pharmaceuticals
  • 5.3. Animal feed
  • 5.4. Others

6. Calcifediol Market Analysis, by Geography

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. USA
    • 6.2.2. Canada
    • 6.2.3. Mexico
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
    • 6.3.3. Others
  • 6.4. Europe
    • 6.4.1. United Kingdom
    • 6.4.2. Germany
    • 6.4.3. France
    • 6.4.4. Italy
    • 6.4.5. Others
  • 6.5. Middle East and Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. Israel
    • 6.5.3. Others
  • 6.6. Asia Pacific
    • 6.6.1. China
    • 6.6.2. Japan
    • 6.6.3. India
    • 6.6.4. South Korea
    • 6.6.5. Indonesia
    • 6.6.6. Thailand
    • 6.6.7. Taiwan
    • 6.6.8. Others

7. Competitive Environment and Analysis

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Emerging Players and Market Lucrativeness
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Vendor Competitiveness Matrix

8. Company Profiles 

  • 8.1. Chemvon Biotechnology Co
  • 8.2. Cayman Chemicals
  • 8.3. Haoyuan Chemexpress Co., Ltd
  • 8.4. Pharmaceutical Research Institute (PRI)
  • 8.5. BOC Sciences
  • 8.6. BLDpharm
  • 8.7. Pharmaffiliates
  • 8.8. ChemScence
  • 8.9. ApexBio Technology